

HR 1476

PLASMA Act

Congress: 119 (2025–2027, Current)

Chamber: House

Policy Area: Health

Introduced: Feb 21, 2025

Current Status: Referred to the Committee on Energy and Commerce, and in addition to the Committee on Ways and Means

Latest Action: Referred to the Committee on Energy and Commerce, and in addition to the Committee on Ways and Means, for a period to be subsequently determined by the Speaker, in each case for consideration of such provisions as fall within the jurisdiction of the committee concerned. (Feb 21, 2025)

Official Text: <https://www.congress.gov/bill/119th-congress/house-bill/1476>

Sponsor

Name: Rep. Hudson, Richard [R-NC-9]

Party: Republican • **State:** NC • **Chamber:** House

Cosponsors (5 total)

Cosponsor	Party / State	Role	Date Joined
Rep. Davis, Donald G. [D-NC-1]	D · NC		Feb 21, 2025
Rep. Murphy, Gregory F. [R-NC-3]	R · NC		Feb 21, 2025
Rep. Peters, Scott H. [D-CA-50]	D · CA		Feb 21, 2025
Rep. Rouzer, David [R-NC-7]	R · NC		May 5, 2025
Rep. Knott, Brad [R-NC-13]	R · NC		Jun 3, 2025

Committee Activity

Committee	Chamber	Activity	Date
Energy and Commerce Committee	House	Referred To	Feb 21, 2025
Ways and Means Committee	House	Referred To	Feb 21, 2025

Subjects & Policy Tags

Policy Area:

Health

Related Bills

Bill	Relationship	Last Action
119 S 694	Identical bill	Feb 24, 2025: Read twice and referred to the Committee on Finance.

Preserving Life-saving Access to Specialty Medicines in America Act or the PLASMA Act

This bill phases-in certain price adjustments for plasma-derived products under the Medicare prescription drug benefit's Manufacturer Discount Program.

Current law requires manufacturers of covered drugs under the Medicare prescription drug benefit to provide a 10% discount for covered drugs during the initial coverage phase (i.e., before a beneficiary reaches the out-of-pocket spending threshold) and a 20% discount during the catastrophic coverage phase (i.e., after a beneficiary reaches the out-of-pocket spending threshold).

The bill phases-in discounts for plasma-derived products over several years, starting with a 1% discount in 2026 for both the initial and catastrophic coverage phases, and ending with a 10% discount beginning in 2030 for the initial coverage phase and a 20% discount beginning in 2032 for the catastrophic coverage phase.

